Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients
- PMID: 19304045
- DOI: 10.1016/j.joms.2008.11.015
Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients
Abstract
Purpose: Osteonecrosis of the jaw (ONJ) is a devastating side effect of long-term bisphosphonate (BP) use. We present the largest case series from a single department.
Materials and methods: This case series included 101 ONJ patients. Data on demographics, medical background, type and duration of BP use, possible triggering events, mode of therapy, and outcome were recorded.
Results: ONJ was associated with intravenous BPs in 85 patients and with oral BPs in 16 patients. It was diagnosed after 48, 27, and 67 months of pamidronate, zoledronic acid, and alendronate use, respectively. Long-term antibiotics and minimal surgical procedures resulted in complete or partial healing in 18% and 52% of the patients, respectively; 30% had no response. There was no association between ONJ and diabetes, steroid and antiangiogenic treatment, or underlying periodontal disease. Diagnostic biopsies aggravated lesions without being informative about pathogenesis. A conservative regimen is our treatment of choice.
Conclusion: Solutions for decreasing morbidity and poor outcome of ONJ remain elusive.
Similar articles
-
A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.Clin Ther. 2007 Aug;29(8):1548-58. doi: 10.1016/j.clinthera.2007.08.008. Clin Ther. 2007. PMID: 17919538 Review.
-
"Bis-phossy jaws" - high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw.J Craniomaxillofac Surg. 2008 Mar;36(2):95-103. doi: 10.1016/j.jcms.2007.06.008. Epub 2008 Jan 30. J Craniomaxillofac Surg. 2008. PMID: 18234504
-
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.J Clin Oncol. 2005 Dec 1;23(34):8580-7. doi: 10.1200/JCO.2005.02.8670. J Clin Oncol. 2005. PMID: 16314620
-
Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.Eur Urol. 2008 Nov;54(5):1066-72. doi: 10.1016/j.eururo.2008.06.070. Epub 2008 Jun 26. Eur Urol. 2008. PMID: 18602738
-
[Bisphosphonates and osteonecrosis of the jaws].Clin Calcium. 2007 Feb;17(2):241-8. Clin Calcium. 2007. PMID: 17272882 Review. Japanese.
Cited by
-
Existing data sources for clinical epidemiology: Scandinavian Cohort for osteonecrosis of the jaw - work in progress and challenges.Clin Epidemiol. 2015 Jan 30;7:107-16. doi: 10.2147/CLEP.S71796. eCollection 2015. Clin Epidemiol. 2015. PMID: 25657594 Free PMC article.
-
Oral bisphosphonate-related osteonecrosis of the jaws: Clinical characteristics of a series of 20 cases in Spain.Med Oral Patol Oral Cir Bucal. 2012 Sep 1;17(5):e751-8. doi: 10.4317/medoral.18041. Med Oral Patol Oral Cir Bucal. 2012. PMID: 22549688 Free PMC article.
-
Prognostic factors for outcome of surgical treatment in medication-related osteonecrosis of the jaw.J Korean Assoc Oral Maxillofac Surg. 2018 Aug;44(4):174-181. doi: 10.5125/jkaoms.2018.44.4.174. Epub 2018 Aug 29. J Korean Assoc Oral Maxillofac Surg. 2018. PMID: 30181984 Free PMC article.
-
[Bisphosphonate-associated osteonecrosis of the jaw].Schmerz. 2015 Apr;29(2):171-8. doi: 10.1007/s00482-014-1499-y. Schmerz. 2015. PMID: 25860198 Review. German.
-
Korean Guideline for the Prevention and Treatment of Glucocorticoid-induced Osteoporosis.J Bone Metab. 2018 Nov;25(4):195-211. doi: 10.11005/jbm.2018.25.4.195. Epub 2018 Nov 30. J Bone Metab. 2018. PMID: 30574464 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical